COVID-19相关肺毛霉病的定义、诊断和管理:印度真菌感染研究论坛与肺科学学会Delphi共识声明
该共识采用改良Delphi法,由26名多学科专家经三轮投票形成,89条陈述中84条达成共识。共识将COVID-19诊断后3个月内发生的肺毛霉病定义为CAPM,推荐柔性支气管镜早期诊断、脂质体两性霉素B(5 mg/kg每日)联合早期手术,并在4-6周评估疗效。
要点
- COVID-19诊断后3个月内发生的肺毛霉病定义为CAPM,分为确诊、很可能和可能。
- 推荐柔性支气管镜以实现早期诊断,并推荐脂质体两性霉素B(5 mg/kg每日)和早期手术作为核心治疗。
- 推荐在4-6周使用临床和影像学参数评估疗效,初始应答后推荐泊沙康唑或艾沙康唑维持治疗。
核心结论
- CAPM是COVID-19罕见但报告不足的并发症,共识提出了定义、诊断和管理的推荐,但仍需更广泛的研究。
研究设计与样本
- 采用改良Delphi法,从参与CAPM管理的多个学科选择26名专家,进行三轮Delphi流程以达成共识(≥70%同意或不同意)或未达成共识。
主要发现
- 89条陈述中84条达成共识。
- COVID-19诊断后3个月内发生的肺毛霉病被标记为CAPM,并进一步分类为确诊、很可能和可能。
- 专家提出了定义以分类COVID-19患者中曲霉病和毛霉病的双重感染。
- 泊沙康唑或艾沙康唑被推荐作为初始应答后的维持治疗,但未就治疗持续时间达成共识。
- 对于疾病稳定或进展的患者,专家推荐使用泊沙康唑或艾沙康唑进行挽救治疗。
关键数值与推荐
- 推荐柔性支气管镜以实现早期诊断。
- 推荐脂质体两性霉素B(5 mg/kg每日)和早期手术作为COVID-19患者毛霉病管理的核心。
- 推荐在4-6周使用临床和影像学参数评估疗效。
临床怎么用
- 临床中可依据共识定义将COVID-19诊断后3个月内发生的肺毛霉病诊断为CAPM,并分类为确诊、很可能和可能。
- 推荐使用柔性支气管镜以实现早期诊断。
- 推荐脂质体两性霉素B(5 mg/kg每日)和早期手术作为CAPM管理的核心。
- 推荐在4-6周使用临床和影像学参数评估疗效,初始应答后推荐泊沙康唑或艾沙康唑维持治疗,但治疗持续时间未达成共识。
- 对于疾病稳定或进展的患者,专家推荐使用泊沙康唑或艾沙康唑进行挽救治疗。
局限性
- 原文指出需要更广泛的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19-associated pulmonary mucormycosis (CAPM) remains an underdiagnosed entity. Using a modified Delphi method, we have formulated a consensus statement for the diagnosis and management of CAPM. We selected 26 experts from various disciplines who are involved in managing CAPM. Three rounds of the Delphi process were held to reach consensus (≥70% agreement or disagreement) or dissensus. A consensus was achieved for 84 of the 89 statements. Pulmonary mucormycosis occurring within 3 months of COVID-19 diagnosis was labelled CAPM and classified further as proven, probable, and possible. We recommend flexible bronchoscopy to enable early diagnosis. The experts proposed definitions to categorise dual infections with aspergillosis and mucormycosis in patients with COVID-19. We recommend liposomal amphotericin B (5 mg/kg per day) and early surgery as central to the management of mucormycosis in patients with COVID-19. We recommend response assessment at 4-6 weeks using clinical and imaging parameters. Posaconazole or isavuconazole was recommended as maintenance therapy following initial response, but no consensus was reached for the duration of treatment. In patients with stable or progressive disease, the experts recommended salvage therapy with posaconazole or isavuconazole. CAPM is a rare but under-reported complication of COVID-19. Although we have proposed recommendations for defining, diagnosing, and managing CAPM, more extensive research is required.
引用
- Muthu V, Agarwal R, Patel A, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. Lancet Infect Dis. 2022. PMID: 35390293. doi:10.1016/S1473-3099(22)00124-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。